XHANCE Approved by FDA as First and Only Medication
ReOpen was the first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis ...
Read moreReOpen was the first ever large placebo-controlled clinical trial program to demonstrate statistically significant reduction of symptoms in chronic sinusitis ...
Read moreALK’s near-term carbon reduction targets for scope 1, 2 and 3 have been validated and approved by the Science Based ...
Read moreApproval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared ...
Read moreTORONTO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (“Psyence Biomed”) is excited to announce the completion of its ...
Read moreDupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE) Approval ...
Read moreMMTC-PAMP is India's First Precious Metals Company to have Science-based Emissions Reduction Targets Approved by the SBTi ...
Read moreEuropean Commission (EC) grants marketing authorization for AGAMREE® for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 ...
Read more© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.
© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.